We propose to use the power and ease of C. elegans genetics in a core capacity to extend existing substance abuse research in new directions. We will use this genetically-tractable organism to pursue novel areas of study related to funded projects and to answer other questions not easily addressed in a mammalian system that are posed by ourselves and the large group of drug abuse researchers at this and neighboring institutions. The end goal of this core-provided research will be to better understand mechanisms of action of drugs of abuse, including identification and elaboration of genes and pathways that are important in drug effects, and to provide a biological system where alterations in nervous system function can be genetically controlled with ease to aid in drug development and drug selection. This core will allow investigators who would not otherwise make use of C. elegans in their own laboratories the opportunity to collaborate with scholars who have extensive experience with this organism and together pursue these novel lines of research investigation. There are three main areas of focus proposed by this C. elegans genetics core. 1) To use C. elegans genetics, pharmacology and a battery of phenotypic assays to understand the effects of alterations in specific genes, specific biological pathways or to better understand the effect of a drug with unclear mechanisms of action. This approach will link the action of drugs with well characterized biological pathways and neurotransmitter systems that can be dissected further using C. elegans genetics. 2) To use C. elegans to carry out reverse and forward genetic screens for genes that are important in mediating phenotypic effects of interest, such as drug-induced phenotypes, or phenotypes produced through alteration of a biological system related to substance abuse. This approach has the potential to identify genes not previously known to be involved with specific drug effects. 3) To use C. elegans to develop living bioassays to take advantage of whole organism drug effects and integration of to vivo biological systems. This approach will allow for refinement of drug development strategies using a whole animal system. These approaches will bring the innovation associated with this powerful genetic system to substance abuse research and generate significant novel findings that will allow researchers to better understand the genetic underpinnings of the mechanisms of action of drugs of abuse.

Public Health Relevance

C. elegans is a powerful genetic model system with a relatively simple nervous system that shares many conserved components with the human brain. Genetic approaches utilizing mutants and transgene techniques will be used to identify genes and biological processes that are important for the action of drugs of abuse and to allow for the development of drugs used to treat substance abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
1P30DA033934-01A1
Application #
8577248
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
1
Fiscal Year
2014
Total Cost
$67,011
Indirect Cost
$19,899
Name
Virginia Commonwealth University
Department
Type
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Kang, Minho; Mischel, Ryan A; Bhave, Sukhada et al. (2017) The effect of gut microbiome on tolerance to morphine mediated antinociception in mice. Sci Rep 7:42658
Jacob, Joanna C; Poklis, Justin L; Akbarali, Hamid I et al. (2017) Ethanol Reversal of Tolerance to the Antinociceptive Effects of Oxycodone and Hydrocodone. J Pharmacol Exp Ther 362:45-52
Dempsey, Sara K; Poklis, Justin L; Sweat, Kacie et al. (2017) Acute Toxicity From Intravenous Use of the Tricyclic Antidepressant Tianeptine. J Anal Toxicol 41:547-550
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2017) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun :
Li, Guangbi; Chen, Zhida; Bhat, Owais M et al. (2017) NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury. J Lipid Res 58:1080-1090
Wolf, Carl E; Poklis, Justin L; Cumpston, Kirk et al. (2017) Acute dilated cardiomyopathy and myocardial injury after combined 4-fluoroamphetamine and modafinil ingestion. Drug Test Anal 9:657-659
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2017) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm :
Wolf, Carl E; Poklis, Justin L; Poklis, Alphonse (2017) Stability of Tetrahydrocannabinol and Cannabidiol in Prepared Quality Control Medible Brownies. J Anal Toxicol 41:153-157
Poklis, Justin L; Wolf 2nd, Carl E; Peace, Michelle R (2017) Ethanol concentration in 56 refillable electronic cigarettes liquid formulations determined by headspace gas chromatography with flame ionization detector (HS-GC-FID). Drug Test Anal 9:1637-1640
Akbarali, Hamid I; Dewey, William L (2017) The gut-brain interaction in opioid tolerance. Curr Opin Pharmacol 37:126-130

Showing the most recent 10 out of 87 publications